Acylated but not des‐acyl ghrelin is neuroprotective in an MPTP mouse model of Parkinson's disease
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The gut hormone ghrelin is widely beneficial in many disease states. However, ghrelin exists in two distinctive isoforms, each with its own metabolic profile. In Parkinson's Disease (PD) acylated ghrelin administration is neuroprotective, however, the role of des‐acylated ghrelin remains unknown. In this study, we wanted to identify the relative contribution each isoform plays using the MPTP model of PD. Chronic administration of acylated ghrelin in mice lacking both isoforms of ghrelin (Ghrelin KO) attenuated the MPTP‐induced loss on tyrosine hydroxylase (TH) neuronal number and volume and TH protein expression in the nigrostriatal pathway. Moreover, acylated ghrelin reduced the increase in glial fibrillary acidic protein and Ionized calcium binding adaptor molecule 1 microglia in the substantia nigra. However, injection of acylated ghrelin also elevated plasma des‐acylated ghrelin, indicating in vivo deacetylation. Next, we chronically administered des‐acylated ghrelin to Ghrelin KO mice and observed no neuroprotective effects in terms of TH cell number, TH protein expression, glial fibrillary acidic protein and ionized calcium binding adaptor molecule 1 cell number. The lack of a protective effect was mirrored in ghrelin‐O‐acyltransferase KO mice, which lack the ability to acylate ghrelin and consequently these mice have chronically increased plasma des‐acyl ghrelin. Plasma corticosterone was elevated in ghrelin‐O‐acyltransferase KO mice and with des‐acylated ghrelin administration. Overall, our studies suggest that acylated ghrelin is the isoform responsible for in vivo neuroprotection and that pharmacological approaches preventing plasma conversion from acyl ghrelin to des‐acyl ghrelin may have clinical efficacy to help slow or prevent the debilitating effects of PD. image Ghrelin exists in the plasma as acyl and des‐acyl ghrelin. We determined the form responsible for in vivo neuroprotection in a mouse model of Parkinson's disease. Although exogenous acyl ghrelin is deacylated in situ to des‐acyl, only acyl ghrelin was neuroprotective by attenuating dopamine cell loss and glial activation. Acyl ghrelin is a therapeutic option to reduce Parkinson's Disease progression. Cover Image for this issue: doi: 10.1111/jnc.13316.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans
Cummings, D. E., Purnell, J. Q., Frayo, R. S., Schmidova, K., Wisse, B. E., & Weigle, D. S. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1714 · Cited by 2,940
Ghrelin enhances appetite and increases food intake in humans
Wren, A. M., Seal, L. J., Cohen, M. A., Brynes, A. E., Frost, G. S., Murphy, K. G., Dhillo, W. S., Ghatei, M. A., & Bloom, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8111 · Cited by 2,494
Cortisol levels during human aging predict hippocampal atrophy and memory deficits
Lupien, S. J., de Leon, M., de Santi, S., Convit, A., Tarshish, C., Nair, N. P. V., Thakur, M., McEwen, B. S., Hauger, R. L., & Meaney, M. J. (1998) · Nature Neuroscience · doi:10.1038/271 · Cited by 1,653
Ghrelin controls hippocampal spine synapse density and memory performance
Diano, S., Farr, S. A., Benoit, S. C., McNay, E. C., da Silva, I., Horvath, B., Gaskin, F. S., Nonaka, N., Jaeger, L. B., Banks, W. A., et al. (2006) · Nature Neuroscience · doi:10.1038/nn1656 · Cited by 828 · cited 2×
“Ghrelin also has many nonmetabolic roles, such as reducing anxiety and stress (Spencer et al. 2012), enhancing learning and memory (Diano et al. 2006) and neuroprotection in PD (Andrews et al. 2009; Moon et al. 2009).”
BackgroundLi, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589 · cited 2×
“dopamine neurons to prevent neurodegeneration in mouse models of PD (Bertilsson et al. 2008; Li et al. 2009).”
BackgroundExenatide and the treatment of patients with Parkinson's disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529
Bertilsson, G., Patrone, C., Zachrisson, O., Andersson, A., Dannaeus, K., Heidrich, J., Kortesmaa, J., Mercer, A., Nielsen, E., Rönnholm, H., et al. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21483 · Cited by 345
Andrews, Z. B., Erion, D., Beiler, R., Liu, Z.-W., Abizaid, A., Zigman, J., Elsworth, J. D., Savitt, J. M., DiMarchi, R., Tschöp, M., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3890-09.2009 · Cited by 289
Self-citationGhrelin regulates the hypothalamic-pituitary-adrenal axis and restricts anxiety after acute stress
Spencer, S. J., Xu, L., Clarke, M. A., Lemus, M., Reichenbach, A., Geenen, B., Kozicz, T., & Andrews, Z. B. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.010 · Cited by 241
Moon, M., Kim, H. G., Hwang, L., Seo, J.-H., Kim, S., Hwang, S., Kim, S., Lee, D., Chung, H., Oh, M. S., et al. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9037-x · Cited by 203 · cited 3×
“Ghrelin also has many nonmetabolic roles, such as reducing anxiety and stress (Spencer et al. 2012), enhancing learning and memory (Diano et al. 2006) and neuroprotection in PD (Andrews et al. 2009; Moon et al. 2009).”
BackgroundResult
Cited by
Microbiome, probiotics and neurodegenerative diseases: deciphering the gut brain axis
Westfall, S., Lomis, N., Kahouli, I., Dia, S. Y., Singh, S. P., & Prakash, S. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2550-9 · Cited by 541
Assessments of plasma ghrelin levels in the early stages of Parkinson's disease
Song, N., Wang, W., Jia, F., Du, X., Xie, A., He, Q., Shen, X., Zhang, J., Rogers, J. T., Xie, J., et al. (2017) · Movement Disorders · doi:10.1002/mds.27095 · Cited by 67
Direct and indirect effects of lipids on microglia function
Leyrolle, Q., Layé, S., & Nadjar, A. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134348 · Cited by 50
Russo, C., Valle, M. S., Russo, A., & Malaguarnera, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113432 · Cited by 40
Stievenard, A., Méquinion, M., Andrews, Z. B., Destée, A., Chartier-Harlin, M.-C., Viltart, O., & Vanbesien-Mailliot, C. C. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.11.021 · Cited by 39
“Furthermore, MPTP injections in homozygous knockout mice lacking ghrelin or its receptor induce a higher rate of neuronal death compared to wild type mice, suggesting a protective role of endogenous ghrelin against MPTP toxicity (Andrews et al., 2009; Bayliss et al., 2016a).”
BackgroundInfluentialSelf-citationHornsby, A. K. E., Buntwal, L., Carisi, M. C., Santos, V. V., Johnston, F., Roberts, L. D., Sassi, M., Mequinion, M., Stark, R., Reichenbach, A., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100120 · Cited by 35
“Regeneron Pharmaceuticals (Tarrytown, NY, USA) Bayliss et al.(37)”
BackgroundSelf-citationAcylated Ghrelin is Protective Against 6-OHDA-induced Neurotoxicity by Regulating Autophagic Flux
He, X., Yuan, W., Liu, F., Feng, J., & Guo, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.586302 · Cited by 21
Emerging roles of leptin in Parkinson’s disease: Chronic inflammation, neuroprotection and more?
Regensburger, M., Rasul Chaudhry, S., Yasin, H., Zhao, Y., Stadlbauer, A., Buchfelder, M., & Kinfe, T. (2023) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2022.09.010 · Cited by 17
Metadata
- Authors
- Bayliss, J. A., Lemus, M., Santos, V. V., Deo, M., Elsworth, J. D., & Andrews, Z. B.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2016-03-11
- Volume
- 137
- Issue
- 3
- Pages
- 460-471
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2263698418
- Cited by
- 56
- References
- 13
- FWCI
- 7.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.